Hematology Pills

Ph+ ALL without chemotherapy: when TKIs reshape the immune response – A dialogue between Robin Foà, Filippo Milano e Michela Ansuinelli

In this episode, Prof. Robin Foà and Dr. Filippo Milano explore the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), focusing on the transition from intensive chemotherapy and transplantation toward targeted therapies combined with immunotherapy. What emerges from the discussion is not only a new therapeutic strategy, but a deeper understanding of how these treatments profoundly reshape the immune system. The conversation centers on the biological effects of combining tyrosine kinase inhibitors with blinatumomab, revealing unexpected patterns of immune activation. Patients treated with Dasatinib showed significant expansion of T cells and NK cells, while the addition of blinatumomab further enhanced immune responses and reduced immunosuppressive regulatory T cells. Particularly striking was the observation that patients achieving early complete molecular responses also displayed the strongest immune modulation, suggesting a direct link between immune activation and clinical outcome. The episode also examines the differences between Dasatinib and Ponatinib. While Dasatinib appears to induce a broad quantitative immune response, Ponatinib seems to act more through qualitative and phenotypic changes, promoting maturation and functional activity of immune effector cells. These findings highlight how different TKIs may interact with the immune system in distinct ways, opening new perspectives for individualized treatment strategies. Looking ahead, the discussion expands to the broader role of the tumor microenvironment, checkpoint inhibition, and CAR-T cell therapy, emphasizing how future advances in Ph+ ALL will increasingly depend on understanding the dialogue between leukemia cells and host immunity at the single-cell level. A thoughtful exploration of how targeted therapy and immunotherapy are redefining the concept of leukemia treatment—moving beyond disease control toward immune-driven eradication of residual disease.

AI in Hematology and Beyond: Transforming Diagnostics, Research, and Care – A dialogue between Robin Foà and Filippo Milano

In this episode, Prof. Robin Foà and Dr. Filippo Milano explore the rapidly expanding role of Artificial Intelligence in medicine, reflecting on a transformation that feels both inevitable and profound. Much like past technological revolutions, AI is already reshaping daily clinical practice—supporting communication, improving academic writing, and streamlining routine tasks—while quietly redefining how physicians interact with information. The discussion moves into concrete clinical applications, from radiology and pathology to hematology, where AI is accelerating diagnostics and enhancing the analysis of complex biological data. Large-scale projects and global datasets are becoming accessible through machine learning, while real-time tools are beginning to assist physicians directly during patient encounters. These advances raise the possibility of more efficient care, improved outcomes, and more precise decision-making. Yet, alongside these opportunities, important concerns emerge. The reliability of AI-generated information, risks to academic integrity, and the protection of sensitive patient data all require careful consideration. Above all, the conversation returns to a central question: how will AI influence the human dimension of medicine? While technology can augment clinical reasoning, the empathy, trust, and personal connection between doctor and patient remain irreplaceable. A balanced and thought-provoking dialogue on the promises and limits of AI—where innovation must evolve hand in hand with responsibility.

Iron Biology Unveiled: Hepcidin, Erythroferrone and the Modern Understanding of Iron Metabolism – A dialogue between Robin Foà, Filippo Milano e Clara Camaschella

In this episode, Prof. Robin Foà and Dr. Filippo Milano are joined by Dr. Clara Camaschella to explore the evolution of iron metabolism, tracing one of the most elegant and coherent stories in modern hematology. From the early conceptual models of iron regulation to the molecular breakthroughs that defined the field, the discussion reflects on what has been described as a true “golden age” of iron biology. The conversation revisits the fundamental principles of iron homeostasis, highlighting the central role of recycling over absorption and the absence of a regulated excretory pathway—features that make systemic control both essential and uniquely complex. From the pioneering work of Clement Finch to the discovery of HFE and the unraveling of genetic heterogeneity, the speakers guide listeners through the key milestones that shaped current understanding. At the heart of the episode is the discovery of hepcidin, the master regulator of iron metabolism, and the mechanisms that govern its interaction with ferroportin. The dialogue also explores the role of erythroferrone in linking erythropoiesis to iron availability, providing a molecular explanation for long-standing physiological hypotheses and shedding light on conditions such as thalassemia. Despite these advances, therapeutic strategies remain rooted in traditional approaches such as phlebotomy, raising important questions about the translation of molecular insights into clinical practice. Looking ahead, the discussion expands toward emerging fields including ferroptosis, immunity, and the role of iron in cardiovascular biology. A rich and reflective journey through discovery, this episode captures both the clarity and the complexity of iron metabolism—an essential system where biology, genetics, and clinical medicine converge.

The Cost of Progress: Funding, Pharma, and the Future of Hematology – A dialogue between Robin Foà e Filippo Milano

In this episode, Prof. Robin Foà and Dr. Filippo Milano reflect on a striking paradox: while research has revolutionized hematology over the past decades, the sustainability of this progress is now in question. Innovation has transformed patient outcomes, yet rising costs and shrinking public funding threaten to slow the pace of discovery. The discussion highlights the growing crisis of academic support, from declining NIH grant success rates in the United States to shifting governmental priorities in Europe. As public investment contracts, the pharmaceutical industry has taken a leading role in driving research—reshaping priorities toward larger markets and increasing the financial burden of clinical trials. At the same time, the soaring costs of advanced diagnostics, such as next-generation sequencing and measurable residual disease monitoring, risk widening disparities in access to care across countries. Philanthropy emerges as a crucial, though complex, pillar sustaining research—whether through major private donations in the US or collective funding models like AIRC in Italy. The episode closes with a sober reflection on how geopolitical tensions further fragment scientific collaboration, reminding us that progress in hematology depends not only on discovery, but on shared commitment and global cooperation. A thoughtful and timely conversation on the future of innovation in our field.

From chemotherapy to targeted precision: A paradigm shift in the frontline treatment of Ph+ ALL - A dialogue between Robin Foà, Filippo Milano and Sabina Chiaretti

In this episode, Prof. Robin Foà, Prof. Filippo Milano and Prof. Sabina Chiaretti explore the first results of a worldwide randomized phase 3 trial that challenges a long-standing paradigm in adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL): the necessity of frontline chemotherapy. The discussion focuses on a direct comparison between a fully chemo-free strategy—combining Ponatinib and Blinatumomab—and the conventional standard of care based on Imatinib plus chemotherapy. The trial enrolled 236 patients with no upper age limit and introduced age-adapted dosing of Ponatinib alongside strictly biology-driven criteria for allogeneic transplantation, based on molecular response, ABL1 mutations, and the Ikaros-plus genotype. Intensified central nervous system prophylaxis addressed the historically high risk of CNS relapse in this disease. The speakers highlight the superiority of the chemo-free arm, which achieved higher hematological and molecular remission rates, improved event-free survival, and a marked reduction in the need for transplantation. These benefits were accompanied by better tolerability, with fewer severe adverse events and no excess cardiovascular toxicity compared with chemotherapy. Looking ahead, the episode reflects on the broader clinical implications of these findings, particularly for elderly patients and those unfit for intensive therapy. The discussion also opens the door to the possibility of long-term treatment-free remission in patients achieving deep and durable molecular responses, while acknowledging ongoing challenges in global access to advanced diagnostics and targeted therapies. A concise yet in-depth conversation on how precision medicine is reshaping the future of Ph+ ALL—moving the field closer to effective, chemotherapy-free frontline care.